Advisory panel meeting rescheduled pending results from 3-shot dose study. CDC study shows protection from boosters weakens after 3-4 months. New monoclonal antibody cleared to treat omicron.
FDA delays action on youngster vaccines
FDA delays action on youngster vaccines
FDA delays action on youngster vaccines
Advisory panel meeting rescheduled pending results from 3-shot dose study. CDC study shows protection from boosters weakens after 3-4 months. New monoclonal antibody cleared to treat omicron.